Mylan/AHP Maxzide agreement will return product rights to Mylan in five years.
Executive Summary
MYLAN WILL REGAIN EXCLUSIVE RIGHTS TO MAXZIDE FROM AMERICAN HOME PRODUCTS in five years under an agreement covering the triamterene/hydrochlorothiazide products Maxzide and Maxzide-25 announced July 2. After a five-year transition during which Mylan "will pay American Home Products specific amounts," all "financial obligations stop and Mylan will retain all rights to the products, trademarks and tradedress," Mylan said. AHP will continue to market the products in Europe. Generic competition to Maxzide is just beginning: Sidmak's ANDA for a version of Maxzide-25 was approved April 26.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth